BMO Capital Maintains Market Perform on Mirati Therapeutics, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman maintains a Market Perform rating on Mirati Therapeutics (NASDAQ:MRTX) and lowers the price target from $50 to $40.
May 25, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BMO Capital maintains a Market Perform rating on Mirati Therapeutics and lowers the price target from $50 to $40.
The lowered price target from BMO Capital indicates a less optimistic outlook for Mirati Therapeutics. This could lead to a short-term negative impact on the stock price as investors may adjust their expectations based on the new price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100